There have been recent advances in the surgical approach to respectable esophageal cancer. In addition, despite the paucity of level 1 data, regardless of histology (squamous cell or adenocarcinoma), neo-adjuvant chemoradiotherapy has evolved into a de facto standard of care for resectable disease. Pathologic response rate is a surrogate for a more favorable outcome. In addition, there are a number of molecularly targeted agents that may have clinical utility for these patients. Current clinical trials have been designed with a translational research component to define which patients may benefit from the incorporation of these novel agents alongside standard combined-modality approaches.
- Esophageal cancer
ASJC Scopus subject areas